Disease or Syndrome – Page 69

RFK Jr. Backtracks on Vaccine Pledge, Announces Review of Childhood Immunization Schedule

9 months ago talkbio0Tagged CHARGE Syndrome, childhood vaccine schedule, Confirmation, Disease Outbreaks, measles, public health medicine (field), Robert F. Kennedy, Secretary, Senate

Robert F. Kennedy Jr., HHS Secretary, childhood vaccine schedule, review, controversy, public health, measles outbreak, Senate confirmation

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

9 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

GSK’s Penmenvy Approved: New 5-in-1 Meningococcal Vaccine Enters U.S. Market

9 months ago talkbio0Tagged Approved, Invasive meningococcal disease, MenABCWY, Meningococcal vaccine, Penmenvy, SmithKline Beecham, United States Food and Drug Administration, Vaccines

Penmenvy, GSK, meningococcal vaccine, FDA approval, 5-in-1 vaccine, MenABCWY, invasive meningococcal disease (IMD)

AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation

9 months ago talkbio0Tagged Artificial Intelligence, Atrial Fibrillation, Cardiac ablation, Electrophysiology (science), Medical service, Pulmonary veins, TAILORED-AF

Volta Medical, artificial intelligence, cardiac ablation, atrial fibrillation, TAILORED-AF trial, pulmonary vein isolation, electrophysiology

Solid Biosciences’ DMD Gene Therapy Shows Promising Early Results, Driving Stock Surge

9 months ago talkbio0Tagged Clinical Trials, gene therapy, Muscular Dystrophy, Duchenne, SGT-003, Solid Biosciences, surge

Duchenne muscular dystrophy (DMD), gene therapy, SGT-003, microdystrophin, clinical trial, stock surge, Solid Biosciences

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

9 months ago talkbio0Tagged Antisense, Biogen, Drug Development, Epilepsy, Infantile Severe Myoclonic Epilepsy, Infrequent, Oligonucleotides, pharmaceutical partnership, Stoke, Zorevunersen

Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

9 months ago talkbio0Tagged Arbitrating, asset, Biosciences, Clinical Trials, Failure (biologic function), Fraud, Freezing, Hypertensive disease, kilobase pairs, Nordisk, Ocedurenone

Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration

AlgoTx’s ATX01 Shows Promise Despite Missing Primary Endpoint in Phase 2 CIPN Trial

9 months ago talkbio0Tagged AlgoTx, ATX01, Effect, non-opioid pain relief, Peripheral neuropathy due to and following antineoplastic therapy, Phase 2 trial, Placebos, topical amitriptyline

AlgoTx, ATX01, chemotherapy-induced peripheral neuropathy (CIPN), Phase 2 trial, placebo effect, non-opioid pain relief, topical amitriptyline

Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future

9 months ago talkbio0Tagged Artificial Intelligence, Cancer Vaccines, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Discovery, Gene Modification, Investments, personalized therapies, Platform technologies, Precision Medicine, solid-state batteries

CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation

GSK’s Penmenvy Gains FDA Approval, Joining Pfizer in 5-in-1 Meningococcal Vaccine Market

9 months ago talkbio0Tagged Adolescent (age group), Approved, Invasive meningococcal disease, Meningococcal vaccine, Penmenvy, Pfizer, SmithKline Beecham, United States Food and Drug Administration, Vaccines, Young Adult

Penmenvy, GSK, FDA approval, meningococcal vaccine, 5-in-1 vaccine, Pfizer, Penbraya, invasive meningococcal disease (IMD), adolescents and young adults